Jack Allen
Stock Analyst at Baird
(1.03)
# 3,929
Out of 5,131 analysts
42
Total ratings
41.18%
Success rate
-10.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $44 | $55.30 | -20.43% | 3 | Nov 11, 2025 | |
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $14.15 | +352.30% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $4.86 | +146.91% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.07 | +273.83% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.67 | +438.92% | 3 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $12.00 | +233.33% | 2 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $64.87 | +63.40% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $11.43 | +57.48% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $7.15 | +2,417.48% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $0.57 | +1,310.19% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $32.65 | +157.31% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.76 | +184.09% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.26 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.90 | +130.77% | 1 | Oct 7, 2021 |
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Neutral
Price Target: $52 → $44
Current: $55.30
Upside: -20.43%
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $14.15
Upside: +352.30%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $4.86
Upside: +146.91%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.07
Upside: +273.83%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.67
Upside: +438.92%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $12.00
Upside: +233.33%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $64.87
Upside: +63.40%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $11.43
Upside: +57.48%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $7.15
Upside: +2,417.48%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $0.57
Upside: +1,310.19%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $32.65
Upside: +157.31%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.76
Upside: +184.09%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $4.26
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.90
Upside: +130.77%